B cell receptor signaling in chronic lymphocytic leukemia

Trends in Immunology

Volumn 34, Issue 12, 2013, Pages 592-601

  Burger, Jan A ^a   Chiorazzi, Nicholas ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

B cell receptor; Bruton's tyrosine kinase; Chronic lymphocytic leukemia; Microenvironment; Phosphoinositide 3 kinase ; Spleen tyrosine kinase

Indexed keywords

ADAPTOR PROTEIN; ADENOSINE TRIPHOSPHATE; AVL 292; B LYMPHOCYTE RECEPTOR; BREAST CANCER RESISTANCE PROTEIN; BRUTON TYROSINE KINASE; CARBON TETRACHLORIDE; CD40 ANTIGEN; CD40 LIGAND; CXCL13 CHEMOKINE; FIBRONECTIN; FOSTAMATINIB; HETERODIMER; IBRUTINIB; IDELALISIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAIN; IPI 145; LECTIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE; P 142 76; P 505 15; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C GAMMA; PROTEIN KINASE C; PROTEIN KINASE ZAP 70; RHEUMATOID FACTOR; STROMAL CELL DERIVED FACTOR 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIMENTIN;

ADAPTIVE IMMUNITY; ANTIBODY COMBINING SITE; CANCER GROWTH; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; HEMATOPOIETIC CELL; HUMAN; LARGE CELL LYMPHOMA; LEUKEMIA REMISSION; MANTLE CELL LYMPHOMA; MUTATION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION;

B CELL RECEPTOR; BRUTON'S TYROSINE KINASE; CHRONIC LYMPHOCYTIC LEUKEMIA; MICROENVIRONMENT; PHOSPHOINOSITIDE 3-KINASE Δ; SPLEEN TYROSINE KINASE;

ANIMALS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE ACTIVATION; RECEPTORS, ANTIGEN, B-CELL; SIGNAL TRANSDUCTION;

EID: 84888440844     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2013.07.002     Document Type: Review

References (130)

1. Stein H., et al. Immunohistologic analysis of the organization of normal lymphoid tissue and non-Hodgkin's lymphomas. J. Histochem. Cytochem. 1980, 28:746-760.
2. Burger J.A., et al. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000, 96:2655-2663.
3. Burkle A., et al. Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. Blood 2007, 110:3316-3325.
4. Patten P.E., et al. CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. Blood 2008, 111:5173-5181.
5. Ruan J., et al. Magnitude of stromal hemangiogenesis correlates with histologic subtype of non-Hodgkin's lymphoma. Clin. Cancer Res. 2006, 12:5622-5631.
6. Burger J.A., et al. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 2009, 114:3367-3375.
7. Messmer B.T., et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J. Clin. Invest. 2005, 115:755-764.
8. LeBien T.W., Tedder T.F. B lymphocytes: how they develop and function. Blood 2008, 112:1570-1580.
9. Goodnow C.C., et al. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature 2005, 435:590-597.
10. Burger J.A. Nurture versus nature: the microenvironment in chronic lymphocytic leukemia. Hematol. Am. Soc. Hematol. Educ. Program 2011, 2011:96-103.
11. Stevenson F.K., et al. B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2011, 118:4313-4320.
12. Woyach J.A., et al. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood 2012, 120:1175-1184.
13. Efremov D.G., et al. Novel agents and emerging strategies for targeting the B-cell receptor pathway in CLL. Mediterr. J. Hematol. Infect. Dis. 2012, 4:e2012067.
14. Davis R.E., et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010, 463:88-92.
15. Duhren-von Minden M., et al. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature 2012, 489:309-312.
16. Shaffer A.L., et al. Pathogenesis of human B cell lymphomas. Annu. Rev. Immunol. 2012, 30:565-610.
17. Chiorazzi N., Efremov D.G. Chronic lymphocytic leukemia: a tale of one or two signals?. Cell Res. 2013, 23:182-185.
18. Wiestner A. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Blood 2012, 120:4684-4691.
19. Young R.M., Staudt L.M. Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat. Rev. Drug Discov. 2013, 12:229-243.
20. Binder M., et al. CLL B-cell receptors can recognize themselves: alternative epitopes and structural clues for autostimulatory mechanisms in CLL. Blood 2013, 121:239-241.
21. Herishanu Y., et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011, 117:563-574.
22. Liu W., et al. Intrinsic properties of immunoglobulin IgG1 isotype-switched B cell receptors promote microclustering and the initiation of signaling. Immunity 2010, 32:778-789.
23. Damle R.N., et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999, 94:1840-1847.
24. Hamblin T.J., et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999, 94:1848-1854.
25. Wiestner A., et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003, 101:4944-4951.
26. Crespo M., et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N. Engl. J. Med. 2003, 348:1764-1775.
27. Sivina M., et al. CCL3 (MIP-1{alpha}) plasma levels and the risk for disease progression in chronic lymphocytic leukemia (CLL). Blood 2011, 117:1662-1669.
28. Messmer B.T., et al. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J. Exp. Med. 2004, 200:519-525.
29. Stamatopoulos K., et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood 2007, 109:259-270.
30. Chiorazzi N., Ferrarini M. B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Annu. Rev. Immunol. 2003, 21:841-894.
31. Chiorazzi N., et al. Chronic lymphocytic leukemia. N. Engl. J. Med. 2005, 352:804-815.
32. Stevenson F.K., Caligaris-Cappio F. Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood 2004, 103:4389-4395.
33. Rosenwald A., et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J. Exp. Med. 2001, 194:1639-1647.
34. Fais F., et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J. Clin. Invest. 1998, 102:1515-1525.
35. Chiorazzi N., Ferrarini M. Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities. Blood 2011, 117:1781-1791.
36. Klein U., et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J. Exp. Med. 2001, 194:1625-1638.
37. Broker B.M., et al. Chronic lymphocytic leukemic (CLL) cells secrete multispecific autoantibodies. J. Autoimmun. 1988, 1:469-481.
38. Sthoeger Z.M., et al. Production of autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemia. J. Exp. Med. 1989, 169:255-268.
39. Kostareli E., et al. Antigen receptor stereotypy across B-cell lymphoproliferations: the case of IGHV4-59/IGKV3-20 receptors with rheumatoid factor activity. Leukemia 2012, 26:1127-1131.
40. Hoogeboom R., et al. A novel chronic lymphocytic leukemia subset expressing mutated IGHV3-7-encoded rheumatoid factor B-cell receptors that are functionally proficient. Leukemia 2013, 27:738-740.
41. Hoogeboom R., et al. A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi. J. Exp. Med. 2013, 210:59-70.
42. Borche L., et al. Evidence that chronic lymphocytic leukemia B lymphocytes are frequently committed to production of natural autoantibodies. Blood 1990, 76:562-569.
43. Herve M., et al. Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity. J. Clin. Invest. 2005, 115:1636-1643.
44. Lanemo Myhrinder A., et al. A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. Blood 2008, 111:3838-3848.
45. Chu C.C., et al. Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA. Blood 2008, 112:5122-5129.
46. Binder M., et al. Stereotypical chronic lymphocytic leukemia B-cell receptors recognize survival promoting antigens on stromal cells. PLoS ONE 2010, 5:e15992.
47. Krysov S., et al. Surface IgM of CLL cells displays unusual glycans indicative of engagement of antigen in vivo. Blood 2010, 115:4198-4205.
48. Chen L., et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2002, 100:4609-4614.
49. Chen L., et al. ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. Blood 2005, 105:2036-2041.
50. Nolz J.C., et al. ZAP-70 is expressed by a subset of normal human B-lymphocytes displaying an activated phenotype. Leukemia 2005, 19:1018-1024.
51. Cutrona G., et al. B lymphocytes in humans express ZAP-70 when activated in vivo. Eur. J. Immunol. 2006, 36:558-569.
52. Scielzo C., et al. ZAP-70 is expressed by normal and malignant human B-cell subsets of different maturational stage. Leukemia 2006, 20:689-695.
53. Rassenti L.Z., et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N. Engl. J. Med. 2004, 351:893-901.
54. Chen L., et al. ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia. Blood 2008, 111:2685-2692.
55. Gobessi S., et al. ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells. Blood 2007, 109:2032-2039.
56. Richardson S.J., et al. ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL). Blood 2006, 107:3584-3592.
57. Messmer D., et al. Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib. Blood 2011, 117:882-889.
58. Calpe E., et al. ZAP-70 enhances migration of malignant B lymphocytes toward CCL21 by inducing CCR7 expression via IgM-ERK1/2 activation. Blood 2011, 118:4401-4410.
59. Vaisitti T., et al. CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells. Leukemia 2010, 24:958-969.
60. Sivina M., et al. CCL3 (MIP-1alpha) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood 2011, 117:1662-1669.
61. Yan X.J., et al. Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia. Blood 2011, 118:5201-5210.
62. Schall T.J., et al. Human macrophage inflammatory protein alpha (MIP-1 alpha) and MIP-1 beta chemokines attract distinct populations of lymphocytes. J. Exp. Med. 1993, 177:1821-1826.
63. Krzysiek R., et al. Antigen receptor engagement selectively induces macrophage inflammatory protein-1 alpha (MIP-1 alpha) and MIP-1 beta chemokine production in human B cells. J. Immunol. 1999, 162:4455-4463.
64. Eberlein J., et al. Comprehensive assessment of chemokine expression profiles by flow cytometry. J. Clin. Invest. 2010, 120:907-923.
65. Burger J.A., et al. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood 2009, 113:3050-3058.
66. Shaffer A.L., et al. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity 2000, 13:199-212.
67. Quiroga M.P., et al. B cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel Syk inhibitor, R406. Blood 2009, 114:1029-1037.
68. Hoellenriegel J., et al. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. Leukemia 2012, 26:1576-1583.
69. Ponader S., et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 2012, 119:1182-1189.
70. Hoellenriegel J., et al. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011, 118:3603-3612.
71. Zucchetto A., et al. CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival. Cancer Res. 2009, 69:4001-4009.
72. Ghia P., et al. Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22. Eur. J. Immunol. 2002, 32:1403-1413.
73. Bystry R.S., et al. B cells and professional APCs recruit regulatory T cells via CCL4. Nat. Immunol. 2001, 2:1126-1132.
74. Castellino F., et al. Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. Nature 2006, 440:890-895.
75. Lam K.P., et al. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell 1997, 90:1073-1083.
76. Kraus M., et al. Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer. Cell 2004, 117:787-800.
77. Contri A., et al. Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J. Clin. Invest. 2005, 115:369-378.
78. Gobessi S., et al. Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells. Leukemia 2008, 23:686-697.
79. Muzio M., et al. Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy. Blood 2008, 112:188-195.
80. Hewamana S., et al. The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood 2008, 111:4681-4689.
81. Refaeli Y., et al. The B cell antigen receptor and overexpression of MYC can cooperate in the genesis of B cell lymphomas. PLoS Biol. 2008, 6:e152.
82. Philippen A., et al. SYK carries no activating point mutations in patients with chronic lymphocytic leukaemia (CLL). Br. J. Haematol. 2010, 150:633-636.
83. Thompson A.A., et al. Aberrations of the B-cell receptor B29 (CD79b) gene in chronic lymphocytic leukemia. Blood 1997, 90:1387-1394.
84. Gobessi S., et al. Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells. Leukemia 2009, 23:686-697.
85. Apollonio B., et al. Targeting B-cell anergy in chronic lymphocytic leukemia. Blood 2013, 121:3879-3888.
86. Greaves M. Clonal expansion in B-CLL: Fungal drivers or self-service?. J. Exp. Med. 2013, 210:1-3.
87. Wu C.J. CLL clonal heterogeneity: an ecology of competing subpopulations. Blood 2012, 120:4117-4118.
88. Dar A.C., Shokat K.M. The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling. Annu. Rev. Biochem. 2011, 80:769-795.
89. Singh J., et al. Targeted covalent drugs of the kinase family. Curr. Opin. Chem. Biol. 2010, 14:475-480.
90. Friedberg J.W., et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010, 115:2578-2585.
91. Advani R.H., et al. Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J. Clin. Oncol. 2012, 31:88-94.
92. de Gorter D.J., et al. Bruton's tyrosine kinase and phospholipase Cgamma2 mediate chemokine-controlled B cell migration and homing. Immunity 2007, 26:93-104.
93. de Rooij M.F., et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 2012, 119:2590-2594.
94. Genevier H.C., et al. Expression of Bruton's tyrosine kinase protein within the B cell lineage. Eur. J. Immunol. 1994, 24:3100-3105.
95. Rawlings D.J., et al. Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice. Science 1993, 261:358-361.
96. Vetrie D., et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature 1993, 361:226-233.
97. Tsukada S., et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell 1993, 72:279-290.
98. Conley M.E., et al. Primary B cell immunodeficiencies: comparisons and contrasts. Annu. Rev. Immunol. 2009, 27:199-227.
99. Petro J.B., et al. Bruton's tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement. J. Exp. Med. 2000, 191:1745-1754.
100. Spaargaren M., et al. The B cell antigen receptor controls integrin activity through Btk and PLCgamma2. J. Exp. Med. 2003, 198:1539-1550.
101. Ortolano S., et al. Roles for phosphoinositide 3-kinases, Bruton's tyrosine kinase, and Jun kinases in B lymphocyte chemotaxis and homing. Eur. J. Immunol. 2006, 36:1285-1295.
102. Honigberg L.A., et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:13075-13080.
103. Herman S.E., et al. Bruton's tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011, 117:6287-6296.
104. Yang Y., et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 2012, 21:723-737.
105. Burger J.A., Montserrat E. Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B cell receptor signaling. Blood 2013, 121:1501-1509.
106. Byrd J.C., et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 2013, 369:32-42.
107. Wang M.L., et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 2013, 10.1056/NEJMoa1306220.
108. Srinivasan L., et al. PI3 kinase signals BCR-dependent mature B cell survival. Cell 2009, 139:573-586.
109. Okkenhaug K., Vanhaesebroeck B. PI3K in lymphocyte development, differentiation and activation. Nat. Rev. Immunol. 2003, 3:317-330.
110. Jou S.T., et al. Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex. Mol. Cell. Biol. 2002, 22:8580-8591.
111. Okkenhaug K., et al. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 2002, 297:1031-1034.
112. Ringshausen I., et al. Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta. Blood 2002, 100:3741-3748.
113. Kienle D., et al. Distinct gene expression patterns in chronic lymphocytic leukemia defined by usage of specific VH genes. Blood 2006, 107:2090-2093.
114. Edelmann J., et al. Bone marrow fibroblasts induce expression of PI3K/NF-kappaB pathway genes and a pro-angiogenic phenotype in CLL cells. Leuk. Res. 2008, 32:1565-1572.
115. Burger J.A., et al. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood 1999, 94:3658-3667.
116. Longo P.G., et al. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood 2008, 111:846-855.
117. Lannutti B.J., et al. CAL-101, a p110{delta} selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011, 117:591-594.
118. Herman S.E., et al. Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 2010, 116:2078-2088.
119. Ikeda H., et al. PI3K/p110{delta} is a novel therapeutic target in multiple myeloma. Blood 2010, 116:1460-1468.
120. Turner M., et al. Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk. Nature 1995, 378:298-302.
121. Cheng A.M., et al. Syk tyrosine kinase required for mouse viability and B-cell development. Nature 1995, 378:303-306.
122. Young R.M., et al. Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target. Blood 2009, 113:2508-2516.
123. Zarbock A., et al. Spleen tyrosine kinase Syk is necessary for E-selectin-induced alpha(L)beta(2) integrin-mediated rolling on intercellular adhesion molecule-1. Immunity 2007, 26:773-783.
124. Ganju R.K., et al. Beta-chemokine receptor CCR5 signals through SHP1, SHP2, and Syk. J. Biol. Chem. 2000, 275:17263-17268.
125. Weinblatt M.E., et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum. 2008, 58:3309-3318.
126. Braselmann S., et al. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J. Pharmacol. Exp. Ther. 2006, 319:998-1008.
127. Weinblatt M.E., et al. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N. Engl. J. Med. 2010, 363:1303-1312.
128. Cheson B.D., et al. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J. Clin. Oncol. 2012, 30:2820-2822.
129. Bohmer R., et al. Regulation of developmental lymphangiogenesis by Syk(+) leukocytes. Dev Cell 2010, 18:437-449.
130. Turner M., et al. Tyrosine kinase SYK: essential functions for immunoreceptor signalling. Immunol Today 2000, 21:148-154.